Laboratory products
A parliamentary committee report on PFAS regulation and the latest government life sciences competitiveness indicators, both published in spring 2026, make uncomfortable reading in different ways. For laboratory managers chemical compliance, shrinking budgets, a contracting talent pipeline, and the growing complexity of procurement are already shaping the working environment and these reports indicate that those pressures are set to grow.
Per- and polyfluoroalkyl substances - the family of synthetic chemicals known as PFAS, or more colloquially as ‘forever chemicals’ - have been a growing concern in environmental and public health circles for several years. A cross-party Environmental Audit Committee report published in April 2026 discusses how the UK should regulate on PFAS, and highlights that the Environment Agency has identified over 10,000 potential PFAS contamination hotspots in England but is actively investigating just four of them.
Estimated remediation costs for the highest-risk sites run to between £31 billion and £121 billion. The chemicals themselves are persistent by design and are now detectable in the blood of almost everyone tested. The committee links PFAS exposure to a range of health effects including certain cancers, immune suppression and developmental harms, though the evidence base continues to develop.
For laboratory managers, the most immediate relevance of the PFAS story is likely to be equipment. Fluoropolymer components -- tubing, seals, fittings, valve linings, sample vessels etc are used extensively in analytical instruments precisely because they are chemically inert, solvent-resistant and thermally stable. In many applications they are, for now, irreplaceable. The committee’s report endorses an essential-use framework under which applications that genuinely cannot be substituted would in principle be eligible for time-limited exemptions from future restrictions. Laboratory analytical equipment falls naturally within that category, though it is not named explicitly in the report.
The practical question for a laboratory manager is whether the equipment they currently use, or are considering purchasing, contains PFAS components that could become subject to restriction -- and whether their suppliers have mapped that exposure and engaged with the regulatory process. It is a reasonable question to put to suppliers. Suppliers who are actively monitoring the European Chemicals Agency’s forthcoming risk assessment -- expected by the end of 2026 -- and who understand which of their products might require essential-use exemptions will be better placed to provide continuity of supply and regulatory clarity than those who are not.
A further complication for procurement is that the UK and EU are doing different things on regulation. The EU has been developing a sweeping group-based restriction covering potentially more than 10,000 PFAS substances, with the European Chemicals Agency’s full assessment expected by the end of 2026. The UK’s position, set out in its February 2026 PFAS Plan, which commits to reforming UK REACH by December 2028, is more cautious.
How the UK’s regulatory approach actually unfolds remains to be seen. Will it take a substance by substance approach, manage the problem by regulating by groups of chemicals with similar properties, or go for the sweeping ban envisaged in the EU?
Currently, the government is assessing potential restrictions on PFAS sub-groups, drawing on approaches already proposed within the EU -- a tentative step towards group-based regulation, but well short of the EU’s sweeping class-wide proposal. Environmental groups have criticised the plan for lacking binding phase-out timelines, and the parliamentary committee’s April 2026 report effectively agrees, finding the PFAS Plan long on monitoring commitments but short on decisive action.
The divergence creates a compliance complexity that laboratory managers purchasing from international suppliers -- or whose organisations operate across both markets -- will need to navigate. Equipment or consumables that meet current UK requirements may not meet evolving EU standards, and vice versa. Where purchasing decisions involve products that could be affected by PFAS restrictions on either side of the Channel, it is worth establishing now which regulatory framework governs the product’s market, what the supplier’s position is on compliance, and what the transition plan looks like if exemptions are time-limited. These are questions that repay being asked early rather than when a restriction has already taken effect.
There is also an emerging opportunity worth noting. Tightening PFAS regulation -- on both sides of the Channel -- is driving significant growth in demand for PFAS testing capability. Water companies, environmental consultancies, food safety laboratories and industrial sites all require the means to detect and quantify PFAS at increasingly low concentrations. The analytical techniques involved, principally liquid chromatography-tandem mass spectrometry and high-resolution mass spectrometry, are established in many research and reference laboratories but are being deployed at scale in settings where they were not previously required. For laboratory managers in relevant sectors, this represents both a service opportunity and, in some cases, a new equipment requirement.
But market growth on environmental testing is something of an outlier in the overall picture for UK laboratories.
The Office for Life Sciences published its 2026 Life Sciences Competitiveness Indicators in April, providing the most detailed official assessment of the UK sector’s condition. The picture it presents is one that laboratory managers will recognise: genuine strength in some areas, and a set of structural pressures that have been building for several years and are now showing up clearly in the data.
On the positive side, private investment has held up well. Inward life sciences foreign direct investment reached £2.1 billion in 2024, a 164% increase on 2023, and equity finance raised by UK life sciences companies rose to £4.5 billion. The UK continues to rank highly for pharmaceutical R&D intensity, exceeded only by Switzerland and Belgium among 16 comparator countries.
The pressures, however, are structural and cumulative. Government health R&D spending has declined from 0.15% of GDP in 2020 to 0.12% in 2023. Clinical trial start-up times have lengthened considerably - the median time from application to first patient dose rose from 273 days in 2022 to 338 days in 2023, leaving the UK ranked last among ten comparator countries on that measure. For laboratory managers working in or adjacent to clinical research, this translates directly into longer periods of preparation and uncertainty, more complex planning cycles, and compressed operational timelines once trials do finally begin.
Perhaps the most significant long-term indicator in the report for working laboratory managers is the graduate data. The proportion of UK graduates completing degrees in natural sciences, mathematics and statistics fell from 13.4% in 2019 to 8.0% in 2023, a drop that moved the UK from second to fifth place in international rankings. That is a substantial contraction in the pipeline of people entering scientific roles, and its effects are already being felt.
For laboratory managers, the consequences are practical and immediate. Recruiting scientists with the right technical background is taking longer and costing more. Roles that once attracted several strong candidates may now attract one or two. The institutional knowledge that accumulates in a well-staffed, relatively stable laboratory team - knowledge of instrument quirks, validated methods, supplier relationships, informal troubleshooting protocols - is harder to retain when turnover is higher and replacement staff are less experienced. The burden of training falls more heavily on managers and senior scientists who are already stretched.
The skills gap has a specific procurement dimension. Good laboratory procurement is not purely administrative: it requires enough technical understanding to evaluate competing products, to interrogate supplier claims, to anticipate the validation burden of switching platforms, and to negotiate service contracts that reflect genuine operational requirements. As the pool of staff with that combination of scientific and commercial competence narrows, procurement decisions carry more risk. Mistakes are more likely, and more costly to correct. In this environment, the value of a supplier who provides clear, honest technical guidance -- and who understands the difference between what a laboratory needs and what the supplier would prefer to sell -- increases considerably.
Budget pressure and talent constraints together create a procurement environment that is more demanding than it was five years ago. Laboratory managers and procurement staff in publicly funded organisations are working with budgets that have not kept pace with either inflation or the expanding complexity of their research portfolios. Capital expenditure decisions require more layers of justification. Consumable budgets are scrutinised more closely. The expectation that existing equipment will be maintained and extended rather than routinely replaced has become the default rather than the exception.
In practical terms, this shifts the basis on which supplier relationships are evaluated. Price remains important, but the total cost of ownership -- including installation, validation, training, service, consumables and the cost of downtime -- matters more than it did when budgets were more forgiving. Reliability and technical support carry greater weight. The ability of a supplier to provide comprehensive documentation, regulatory compliance data and method transfer support reduces the internal resource burden on the purchasing laboratory, and is therefore worth something tangible in procurement terms.
There is also growing value in suppliers who are demonstrably well-informed about the regulatory and market environment -- not as a sales technique, but as a genuine service. A supplier who can advise a laboratory manager on the PFAS compliance status of their product range, who monitors UK and EU regulatory developments on behalf of their customers, and who participates in industry bodies that engage with government and standards organisations on these issues, is providing something that saves time and reduces risk. In a sector where internal resource is stretched, that kind of informed, engaged supplier relationship has a value that goes beyond the transaction.
Neither the PFAS report nor the life sciences competitiveness data points to a crisis for UK laboratory science. The investment figures suggest that the sector retains real attractions for private capital, and the research base remains internationally competitive. But the operating environment for laboratory managers and procurement staff has tightened in ways that require a different kind of attention than managing a growing, well-resourced function.
Staying informed about regulatory developments -- particularly around PFAS, where the EU timeline is moving faster than the UK -- is becoming a basic operational requirement rather than a specialist interest. Understanding which equipment and consumables in regular use may be affected by forthcoming restrictions, and asking suppliers direct questions about their compliance position and their engagement with the regulatory process, is a reasonable and prudent step for any laboratory manager responsible for continuity of scientific work.
On the workforce side, the data make a strong case for treating staff development and retention as a strategic priority rather than a budget line to be trimmed when other pressures mount. The cost of losing an experienced scientist or procurement specialist -- in recruitment time, training investment, and the quieter cost of reduced institutional knowledge -- is rarely captured in the calculations made when those budgets are cut. The indicators suggest that the pipeline refilling those roles is narrower than it was, which means the cost of losing experienced staff will only increase.
The full Environmental Audit Committee report, Addressing the risks from Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS), was published on 23 April 2026. The Office for Life Sciences Life Sciences Competitiveness Indicators 2026 is available on gov.uk.
Lab Asia 33.2 April
Product directory
